UBS Group
OKYO

UBS Group’s OKYO Pharma OKYO Stock Holding History

UBS Group’s Portfolio OKYO Stock Details OKYO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.5K Sell
55,009
-4,751
-8% -$7.61K ﹤0.01% 7290
2026
Q1 		$96.2K Buy
59,760
+57,588
+2,651% +$112K ﹤0.01% 7016
2025
Q4 		$4.5K Buy
+2,172
New +$4.71K ﹤0.01% 8825
2025
Q3 		– Sell
-115
Closed -$296 – 10753
2025
Q2 		$296 Buy
+115
New +$195 ﹤0.01% 9886
2025
Q1 		– Sell
-2,998
Closed -$3.45K – 10578
2024
Q4 		$3.45K Buy
2,998
+2,473
+471% +$2.65K ﹤0.01% 8878
2024
Q3 		$536 Sell
525
-1,379
-72% -$1.59K ﹤0.01% 8906
2024
Q2 		$2.27K Buy
+1,904
New +$2.67K ﹤0.01% 8392
2023
Q4 		– Sell
-95
Closed -$176 – 9735
2023
Q3 		$176 Buy
+95
New +$160 ﹤0.01% 8743
2023
Q1 		– Sell
-7,523
Closed -$14.4K – 10145
2022
Q4 		$14.4K Buy
7,523
+6,341
+536% +$13.9K ﹤0.01% 8079
2022
Q3 		$3K Sell
1,182
-2,485
-68% -$5.98K ﹤0.01% 9565
2022
Q2 		$8K Buy
+3,667
New +$8.25K ﹤0.01% 8329

Other funds holding OKYO

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's OKYO Position: Q2 2026 in Review

UBS Group reduced its OKYO Pharma (OKYO) stake by 8% in Q2 2026, selling an estimated $7.61K and leaving 55,009 shares worth $82.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7290.

UBS Group first reported a position in OKYO in Q2 2022 and has held it in 11 quarters since. The position peaked at $96.2K in Q1 2026. 19 funds tracked by Wall St. Rank hold OKYO as of Q2 2026.

  • UBS Group held 55,009 shares of OKYO Pharma worth $82.5K as of Q2 2026.
  • UBS Group sold 4,751 OKYO Pharma shares in Q2 2026, an estimated $7.61K.
  • OKYO Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7290 holding.
  • UBS Group first reported a position in OKYO Pharma in Q2 2022 and has held it in 11 quarters since.
  • UBS Group's OKYO Pharma position peaked at $96.2K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held OKYO Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.